Boule Diagnostics : Nomination Committee for the AGM 2022
October 22, 2021 at 09:14 am EDT
Share
2021-10-22
Boule Diagnostics - Nomination Committee for the 2022 Annual General Meeting
The Annual General Meeting, ("AGM"), 2021 of Boule Diagnostics AB (publ), ("Boule"), decided that a Nomination Committee based on the ownership structure as per September 30, 2021, will be appointed to propose for the AGM of 2022 the following items:
chairman of the AGM,
members of the board of directors,
chairman of the board,
remuneration to the members of the board and remuneration for additional committee work for each board member,
auditor in charge,
remuneration to the auditor,
changes to the principles and instructions for the Nomination Committee, to the extent deemed necessary, and
other items that fall on the Nomination Committee in accordance with The Swedish Corporate Governance Code.
Boule's largest shareholders at the date above were Svolder AB, AB Grenspecialisten and Thomas Eklund, who combined represent just over 34 percent of share capital and votes. Said shareholders have in turn nominated Ulf Hedlundh (Svolder AB), Emil Hjalmarsson (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted and elected Ulf Hedlundh as chairman of the committee and Peter Ehrenheim, the chairman of the board, as an adjunct member of the Nomination Committee.
Shareholders who wish to contact the Nomination Committee are welcome to contact the committee's chairman, Ulf Hedlundh, by email at ulf.hedlundh@svolder.seor by phone on +46 8-440 37 70. To ensure that proposals will have enough time to be evaluated properly, proposals should be submitted by February 1, 2022, at the latest.
For further information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone. +46 (0)70-689 05 90 Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)705-46 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule's own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com
The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on October 22, 2021.
Attachments
Original document
Permalink
Disclaimer
Boule Diagnostics AB published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 13:13:01 UTC.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.